About arGEN-X - http://www.arGEN-X.com
arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.
arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of high quality human antibodies, enabling optimal product choice. SIMPLE Antibodies™ are able to address and modulate any disease target, including complex receptors and highly conserved targets often intractable with other antibody technologies. SIMPLE Antibody™ generated leads are further differentiated as products through enhancement of cell killing properties (POTELLIGENT ®, licensed from BioWa Inc.) and optimization of circulation time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™ technology, to potentiate the clearance of disease-causing autoantibodies.
In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors, as well as in autoimmunity. A second CTA for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, will be filed later in 2013.The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions. SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering. arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV. For further information, please contact: Citigate Dewe Rogerson David Dible Mark Swallow Nina Enegren T: +44-207-282-2949/2948/1050 E: email@example.com arGEN-X Tim Van Hauwermeiren, MSc, eMBA Chief Executive Officer T: +31-6-122-85-257 E: tim.vh@arGEN-X.com Debbie Allen, Ph.D. Senior Director, Business Development T: +44-7974-979479 E: dallen@arGEN-X.com SOURCE arGEN-X